Neurocrine Biosciences Launches Study for New Obesity Treatment, NBIP-'1968

Neurocrine Biosciences Initiates Phase 1 Clinical Study for NBIP-'1968

Neurocrine Biosciences, a prominent biopharmaceutical company based in San Diego, has officially launched a Phase 1 clinical trial examining NBIP-'1968. This investigational drug, a GLP-1/GIP/glucagon receptor triple agonist, is developed to treat obesity, a chronic disease that continues to challenge the healthcare system globally.

The announcement, made on August 7, 2026, represents a significant step in Neurocrine's ongoing commitment to deliver innovative solutions for complex health conditions. Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine, stated, "Obesity is a multifactorial chronic illness influenced by numerous biological pathways, highlighting the urgent need for new treatment options. NBIP-'1968 aims to integrate three different metabolic mechanisms to combat this epidemic effectively."

The Phase 1 study will focus on evaluating the safety and tolerability of NBIP-'1968 in adult participants across various body mass index (BMI) categories, including those who are overweight and obese. With an innovative design, NBIP-'1968 is a long-acting medication intended for once-weekly subcutaneous administration, targeting critical receptors involved in appetite control, energy balance, and glycemic management.

Mechanisms of Action

The formulation of NBIP-'1968 is designed to engage specific receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. By interacting with these receptors, the drug purportedly offers a synergistic effect that may enhance metabolic pathways associated with weight management. The balanced activity towards glucagon receptors aims to maximize the potential metabolic benefits while ensuring tolerability, which is essential given the current challenges patients face with existing therapies.

Neurocrine's broader developmental strategy includes the potential use of NBIP-'1968 in combination with NBIP-'2118, another investigational drug aimed at obesity treatment that is currently in Phase 1 development. "Advancing NBIP-'1968 into clinical testing marks a pivotal moment in our obesity portfolio, allowing us to delve deeper into complementary mechanisms that improve weight loss and help maintain lean body mass," explained Dr. Jude Onyia, Chief Scientific Officer of the company.

Understanding Obesity

Obesity is defined as an excessive accumulation of body fat that poses serious health risks, including type 2 diabetes and cardiovascular disease, among others. The condition involves more than lifestyle choices or personal willpower; it is shaped by intricate biological, environmental, and genetic factors. Presently, obesity is recognized as a global epidemic, affecting a considerable segment of the population and imposing significant burdens on public health systems.

Despite advancements in obesity treatments, the search for additional therapies remains crucial. Current medications face challenges related to gastrointestinal tolerability, dosing requirements, and undesired effects like muscle loss. Neurocrine's focus on investigating multiple approaches emphasizes their commitment to innovating within this therapeutic landscape.

About Neurocrine Biosciences

Founded with a commitment to alleviate human suffering, Neurocrine Biosciences has made significant strides in the development of treatments for under-addressed neurological, psychiatric, endocrine, and immunological disorders. Their expansive portfolio includes FDA-approved therapies and a rich pipeline that promises to tackle various health challenges. Informatively, their continuous investment in research and development drives the company to create impactful treatments that resonate with the needs of patients worldwide.

iWith the initiation of the Phase 1 study of NBIP-'1968, Neurocrine Biosciences showcases its relentless pursuit of solutions for obesity and underscores the importance of advancing scientific understanding towards better health outcomes for patients. Follow Neurocrine on their website and social media for updates on this promising drug and other developments in their pipeline.